Citadel Advisors
INO icon

Citadel Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Citadel Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$498K Buy
+286,352
New +$471K ﹤0.01% 9323
2025
Q4 		– Sell
-12,402
Closed -$27.3K – 13334
2025
Q3 		$29K Sell
12,402
-156,554
-93% -$300K ﹤0.01% 12407
2025
Q2 		$344K Buy
+168,956
New +$324K ﹤0.01% 9481
2025
Q1 		– Sell
-21,728
Closed -$43.6K – 14997
2024
Q4 		$39.8K Buy
+21,728
New +$96.2K ﹤0.01% 12616
2023
Q2 		– Sell
-80,126
Closed -$646K – 14771
2023
Q1 		$788K Buy
80,126
+63,356
+378% +$1.08M ﹤0.01% 7311
2022
Q4 		$314K Sell
16,770
-68,831
-80% -$1.56M ﹤0.01% 9219
2022
Q3 		$1.77M Buy
85,601
+57,102
+200% +$1.46M ﹤0.01% 5820
2022
Q2 		$592K Buy
28,499
+15,535
+120% +$438K ﹤0.01% 8262
2022
Q1 		$558K Sell
12,964
-61,127
-83% -$2.75M ﹤0.01% 9117
2021
Q4 		$4.44M Buy
74,091
+35,194
+90% +$2.82M ﹤0.01% 4537
2021
Q3 		$3.34M Sell
38,897
-41,268
-51% -$4.14M ﹤0.01% 5128
2021
Q2 		$8.92M Sell
80,165
-3,216
-4% -$309K ﹤0.01% 3266
2021
Q1 		$9.29M Buy
83,381
+24,110
+41% +$3.17M ﹤0.01% 3083
2020
Q4 		$6.29M Buy
59,271
+25,349
+75% +$3.37M ﹤0.01% 3295
2020
Q3 		$4.72M Buy
+33,922
New +$7.07M ﹤0.01% 3253
2019
Q3 		– Sell
-2,838
Closed -$100K – 9457
2019
Q2 		$100K Sell
2,838
-1,391
-33% -$55.3K ﹤0.01% 8531
2019
Q1 		$189K Sell
4,229
-467
-10% -$23.5K ﹤0.01% 8249
2018
Q4 		$225K Sell
4,696
-2,465
-34% -$150K ﹤0.01% 7695
2018
Q3 		$477K Sell
7,161
-31,641
-82% -$1.76M ﹤0.01% 6773
2018
Q2 		$1.83M Buy
38,802
+1,218
+3% +$67.2K ﹤0.01% 4248
2018
Q1 		$2.12M Sell
37,584
-21,293
-36% -$1.15M ﹤0.01% 3644
2017
Q4 		$2.92M Buy
58,877
+9,541
+19% +$591K ﹤0.01% 3124
2017
Q3 		$3.75M Buy
+49,336
New +$3.67M ﹤0.01% 2630
2017
Q2 		– Sell
-4,476
Closed -$383K – 7752
2017
Q1 		$356K Buy
4,476
+46
+1% +$3.67K ﹤0.01% 5614
2016
Q4 		$369K Buy
+4,430
New +$401K ﹤0.01% 5369
2016
Q1 		– Sell
-57
Closed -$4.4K – 7326
2015
Q4 		$5K Sell
57
-35,094
-100% -$2.79M ﹤0.01% 8450
2015
Q3 		$2.44M Buy
35,151
+34,220
+3,676% +$2.98M ﹤0.01% 2701
2015
Q2 		$91K Buy
+931
New +$99.5K ﹤0.01% 7168
2015
Q1 		– Sell
-1,195
Closed -$116K – 8672
2014
Q4 		$132K Buy
+1,195
New +$146K ﹤0.01% 6395
2014
Q3 		– Sell
-782
Closed -$97.4K – 8251
2014
Q2 		$101K Buy
782
+474
+154% +$55.9K ﹤0.01% 6214
2014
Q1 		$49K Buy
308
+32
+12% +$4.59K ﹤0.01% 6792
2013
Q4 		$38K Buy
+276
New +$27.6K ﹤0.01% 6184

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's INO Position: Q1 2026 in Review

Citadel Advisors opened a new position in Inovio Pharmaceuticals (INO) in Q1 2026: 286,352 shares worth $498K. The stake represents ﹤0.01% of the portfolio and ranks #9323 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INO as recently as Q3 2025.

Citadel Advisors first reported a position in INO in Q4 2013 and has held it in 32 quarters since. The position peaked at $9.29M in Q1 2021. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Citadel Advisors held 286,352 shares of Inovio Pharmaceuticals worth $498K as of Q1 2026.
  • Inovio Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9323 holding.
  • Citadel Advisors first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 32 quarters since.
  • Citadel Advisors's Inovio Pharmaceuticals position peaked at $9.29M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.